Therapy Areas: Oncology
Telix Pharmaceuticals enters translational research partnership with INSERM and ARRONAX
16 April 2018 -

Telix Pharmaceuticals Ltd (ASX: TLX) has entered into a research partnership with the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale or 'INSERM') and the Accelerator for Research in Radiochemistry and Oncology at Nantes Atlanic (ARRONAX), the biopharmaceutical company disclosed on Monday.

INSERM is a leading translational research organisation that has a strong record of industry engagement and technology development to benefit human health, while ARRONAX is a unique cyclotron (particle accelerator) facility and a world-leader in the production of certain novel radioactive isotopes, including At (astatine).

The research partnership will see Telix explore the feasibility of using several of its clinical targeting agents in combination with astatine.

The agreement will fund sufficient staff and facility time in order for numerous studies to be conducted over a two-year period. This will include preparation for pilot clinical studies in the nuclear medicine department of University Hospital of Nantes.

Under the agreement, Telix will also access a portfolio of intellectual property that has been developed within the Nantes cluster and that has the potential to lead to new products and indications for the company's therapeutic pipeline.